{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"46","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"CA-125 response: The key secondary endpoint of the study will be a CA-125 response, defined as a 50% or greater reduction in baseline CA-125. The null hypothesis will be set at CA-125 response rate of 8.3%, based on the response of single agent letrozole, as reported by Bowman et al (7). The treatment of letrozole and everolimus will be considered promising, based on CA-125, if the observed CA-125 response rate is 30% or more.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Everolimus and Letrozole)"}],"paramType":"NUMBER","populationDescription":"All evaluable patients","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Percentage of Participants With CA-125 Response","type":"SECONDARY","unitOfMeasure":"percentage of patients"}